Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of tedopi plus docetaxel or tedopi plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
Docetaxel;Nivolumab;Tedopi
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of tedopi plus docetaxel or tedopi plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy. ### Output: Docetaxel;Nivolumab;Tedopi